Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over

Asthma (in adults) - corticosteroids: Review Decision - February 2013 information

Asthma (in adults) - corticosteroids: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 147 KB)

Asthma (in adults) - corticosteroids: review proposal - November 2012 information

Asthma (in adults) - corticosteroids: appendix A - provisional matrix of stakeholders (PDF 33 KB)

Asthma (in adults) - corticosteroids: appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 342 KB)

Asthma (in adults) - corticosteroids: appeal  information

Asthma (in adults) - corticosteroids: Appeal information

Appeal details

Appeals received (PDF 421 KB)

Initial scrutiny letter (PDF 32 KB)

NICE response to scrutiny letter (PDF 117 KB)

TEVA response to NICE (PDF 328 KB)

Asthma (in adults) - corticosteroids: Appeal decision (PDF 38 KB)

Asthma (in adults) - corticosteroids: (final appraisal determination)

Consultee and commentator comments on the ACD

General Practice Airways Group (PDF 52 KB)

AstraZeneca (PDF 39 KB)

GSK (PDF 117 KB)

TEVA UK Ltd/IVAX Pharmaceuticals Ltd (PDF 1.4 MB)

Royal College of Nursing (PDF 21 KB)

Department of Health (PDF 13 KB)

Asthma and Allergy Research Group (PDF 23 KB)

Asthma and Allergy Research Group - Additional (PDF 8.4 KB)

Southampton Health Technology Assessments Centre (SHTAC) and the Peninsula Technology Assessment Group (PenTAG) (PDF 16 KB)

Professor Neil Barnes, Consultant Respiratory Physicians nominated by British Thoracic Society (PDF 15 KB)

Asthma (in adults) - corticosteroids: Final appraisal determination information

Asthma (in adults) - corticosteroids: Final appraisal determination (PDF 109 KB)

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 189 KB)

Asthma (in adults) - corticosteroids: Appraisal consultation

Asthma (in adults) - corticosteroids: Appraisal consultation document information

Asthma (in adults) - corticosteroids: Overview (PDF 100 KB)

Asthma (in adults) - corticosteroids: Assessment report (PDF 3.71 MB)

Asthma (in adults) - corticosteroids: Consultee and commentator comments on the assessment report

Altana Pharma Ltd (PDF 91 KB)

AstraZeneca UK Ltd (PDF 177 KB)

GlaxoSmithKline UK (PDF 98 KB)

Meda Pharmaceuticals Ltd (PDF 37 KB)

Ranbaxy (UK) Ltd (PDF 18 KB)

Trinity-Chiesi Pharmaceuticals Ltd (PDF 40 KB)

General Practice Airways Group (GPIAG) (PDF 291 KB)

Napp Pharmaceuticals Ltd (PDF 17 KB)

Respiratory Research Group (PDF 13 KB)

Asthma (in adults) - corticosteroids: Response to Consultee and Commentator comment on the Assessment report (PDF 157 KB)

Asthma (in adults) - corticosteroids: Non-manufacturer submissions

Action Against Allergy (PDF 1.57 MB)

British Lung Foundation (PDF 31 KB)

British Thoracic Society (PDF 29 KB)

Education for Health (PDF 142 KB)

General Practice Airways Group (GPIAG) and Asthma UK (Joint Submission) (PDF 138 KB)

Royal College of Physicians Edinburgh (PDF 33 KB)

Asthma (in adults) - corticosteroids: Manufacturer submissions (executive summary only)

Altana Pharma Ltd (PDF 74 KB)

AstraZeneca UK Ltd (PDF 79 KB)

GlaxoSmithKline UK (PDF 96 KB)

Ivax Pharmaceuticals UK (PDF 77 KB)

Meda Pharmaceuticals Ltd (PDF 47 KB)

Trinity-Chiesi Pharmaceuticals Ltd (PDF 57 KB)

Asthma (in adults) - corticosteroids: Expert written personal statements

Barnes (PDF 30 KB)

Grigg (PDF 13 KB)

Thomas (PDF 28 KB)

Versnel (PDF 23 KB)

Asthma (in adults) - corticosteroids: Final protocol (PDF 114 KB)

Asthma (adults & children over 12) - corticosteroids: Final scope (PDF 40 KB)

Summary of consultee and commentator comments on the draft scope (PDF 150 KB)

Summary of consultee and commentator comments on the provisional matrix (PDF 15 KB)

Archive: Asthma (adults & children over 12) - Provisional Matrix (PDF 40 KB)

Archive: Asthma (adults & children over 12) - Draft scope (PDF 44 KB)

2004/027 NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder information